The AMFm is an innovative financing mechanism designed to expand access to the most effective treatment for malaria, artemisinin-based combination therapies (ACTs). It aims to promote the use of effective antimalarials and drive out ineffective medicines from the market by reducing consumer prices to an affordable level through price negotiations and a buyer co-payment.
No numerical targets were set.
As of 2012, AMFm has subsidized over 300 million ACT treatments. This global subsidy is financed through contributions of US$336 million from UNITAID, the governments of the United Kingdom and Canada, and the Bill & Melinda Gates Foundation. Technical support is provided by members of the Roll Back Malaria Partnership.
Remains to be fully implemented and medicines delivered to countries.
AMFm is managed by the Global Fund.